Abstract

Degeneration of immune organs like thymus and spleen has been discovered in tumor-bearing mice; which increases the difficulties on oncotherapy. More effective drugs which target the protection of immune organs are expected to be researched. In this study; we aim to analyze the antitumor and immunoregulatory activities of seleno-β-lactoglobulin (Se-β-lg) on S180 tumor-bearing mice. Results indicated that Se-β-lg exhibited a remarkable inhibitory effect on S180 solid tumors with the inhibition rate of 48.38%; and protected the thymuses and spleens of S180-bearing mice. In addition, Se-β-lg could also balance the proportions of CD4+ and CD8+ T cells in spleens; thymuses and peripheral bloods; and improve Levels of IL-2; IFN-γ; TNF-α in mice serums. β-lg showed weaker bioactivities while SeO2 showed stronger toxicity on mice. Therefore our results demonstrated that Se-β-lg possessed stronger antitumor and immunoregulatory activities with lower side effects and had the potential to be a novel immunopotentiator and antitumor agent.

Highlights

  • Selenium is essential for the body due to the regulation on activity of seleno-enzyme-glutathione peroxidase [1,2]

  • Se-β-lg could balance the proportions of CD4+ and CD8+ T cells in spleens; thymuses and peripheral bloods; and improve Levels of IL-2; IFN-γ; tumor necrosis factor-α (TNF-α) in mice serums. β-lg showed weaker bioactivities while SeO2 showed stronger toxicity on mice

  • Results showed that Se-β-lg could significantly protect the immune organs in S180-bearing mice, while SeO2 exhibited serious toxic side effects due to the remarkable decrease compared with model group

Read more

Summary

Introduction

Selenium is essential for the body due to the regulation on activity of seleno-enzyme-glutathione peroxidase [1,2]. Mao [10] found polysaccharide termed Se-GP11, extracted and purified from Se-enriched Grifola frondosa exhibited the antitumor effect through improving immunologic function of the tumor bearing mice. Yuan [11] had proved that Se-PFPs could significantly reduce tumors growth on nude mice bearing MDA-MB-231-derived xenograft tumors without toxic side effects. A novel agent, seleno-β-lactoglobulin (Se-β-lg) was synthesized by introducing selenic acid groups to arginine and lysine’s primary amine in β-lg (applying for Chinese patent, No 201410820824.3). The present study was designed to investigate the antitumor and immunoregulatory activities of Se-β-lg on S180 tumor-bearing mice

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call